J&J Modifies Procrit Pricing Practices To Compete With Amgen’s Aranesp 

 
• By The Pink Sheet

Johnson & Johnson is modifying its pricing practices for Procrit (epoetin alfa) to compete with Amgen's Aranesp (darbepoetin alfa)

More from Archive

More from Pink Sheet